The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...
Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
A CDC vaccine advisory committee meeting scheduled for next week has been postponed. It was the first vaccine meeting since ...
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Key CDC vaccine committee meeting pushed ...
The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results